SYRE SPY072: Mixed RA Phase 2, Pivots to Psoriasis and UC

Spyre Therapeutics (NASDAQ: SYRE) reported the rheumatoid arthritis readout from its Phase 2 SKYWAY basket trial on August 26, and the verdict is split: the anti-TL1A antibody SPY072 worked, but not well enough to justify developing it as an RA monotherapy. Spyre is deprioritizing the RA program. The stock closed at $107.36 and slid roughly 14% to about $92 in the reaction.

The numbers are genuinely mixed. In the RA sub-study, 143 patients were randomized to a high dose (48), low dose (48), or placebo (47). On the primary endpoint, change in the DAS28-CRP disease-activity score at week 12, the low dose beat placebo with a -1.9 versus -1.3 improvement (p<0.05). The high dose missed, at -1.5. On ACR20, a measure of 20% symptom improvement, the high dose reached 63% versus 43% for placebo. ACR50 responses were 38% for the low dose versus 19% for placebo, while the strictest bar, ACR70, reached just 13% on the high dose versus 2% on placebo. Safety was clean: adverse events in 27% of treated patients versus 36% on placebo, mostly mild or moderate, with no drug-related serious events.

The drug clearly hit its target. TL1A is a cytokine central to T-cell-driven inflammation, and SPY072 is an extended half-life antibody against it. Both doses reached target drug levels and fully suppressed free TL1A through week 12. What missed was the efficacy bar, not the mechanism. Rheumatoid arthritis is the toughest indication in immunology to break into: biosimilars have pushed down prices, and entrenched TNF, JAK, and IL-6 blockers set a high bar. A new biologic has to be dramatically better, not just nominally, to displace them.

Spyre is redirecting the effort where unmet need is higher. Psoriatic arthritis and axial spondyloarthritis data from SKYWAY are due in Q4 2026, the SKYLINE ulcerative colitis readout lands in September, and a hidradenitis suppurativa combination study with an IL-17A/F antibody is underway. TL1A remains one of the most valuable targets in immunology, with Merck’s $10.8 billion Prometheus buy and Roche’s $7.1 billion Telavant deal setting the stakes. Spyre’s role as the pure-play TL1A bet is covered in this IBD and TL1A breakdown.

What to watch: the September SKYLINE Part A ulcerative colitis readout is the near-term catalyst, and it matters more than RA because UC is where a TL1A drug, Merck’s tulisokibart, has already posted a Phase 3 win. A miss there would cut deeper than this RA result. For parsing topline releases like this one, see how to read a clinical trial press release.

Source: Spyre Therapeutics press release, August 26, 2026

What It Means for the Trade

The 14% slide to roughly $92 is the market doing trial math correctly: the RA data killed the RA indication, and RA was the least valuable basket indication anyway — a market squeezed by biosimilars and dominated by entrenched TNF, JAK, and IL-6 blockers. What the readout did not kill is the mechanism: both doses fully suppressed free TL1A through week 12, safety was clean (adverse events 27% on drug versus 36% on placebo, no drug-related serious events), and the dose-response mosaic — low dose winning DAS28-CRP, high dose winning ACR20 — reads as a genuine but moderate clinical effect, not a dead target.

The trade now concentrates on September. The SKYLINE Part A ulcerative colitis readout is the catalyst that matters more than RA ever did, for one concrete reason: Merck’s tulisokibart has already posted a Phase 3 win in UC, so the TL1A mechanism is validated where it counts commercially. A Spyre UC hit puts the pure-play TL1A name squarely in the path of a validated multibillion-dollar thesis; a miss cuts deeper than this RA result because it would implicate SPY072 specifically, not just the indication choice.

Mechanism and Market Context

Why RA was the wrong battlefield: the endpoint math. A new RA biologic must beat a crowded standard-of-care ladder on durable ACR responses at competitive pricing, and a moderate effect size (ACR70 of 13% on the high dose, however statistically separated from 2% placebo) does not clear the commercial bar. In UC and psoriatic disease, the treatment-experienced population and the fibrosis-adjacent biology give TL1A blockade a clearer differentiation path — which is why Merck paid $10.8 billion for Prometheus and Roche $7.1 billion for Telavant, both on UC-first data.

The dose-response inversion (low dose beating high on the primary, high beating low on ACR20) is worth watching rather than explaining away. It could be noise at n=48 per arm. The psoriatic arthritis and axial spondyloarthritis readouts in Q4 2026 will show which.

Risks and What Could Go Wrong

1. September SKYLINE UC readout. The concentrated binary: a miss there reframes SPY072 as an also-ran behind tulisokibart and the field’s interest deflates quickly.
2. Comparative invisibility. Even a UC win lands Spyre behind Merck’s Phase 3 lead; partnership or acquisition is the exit path, and a weakened data profile weakens it.
3. Basket fatigue. Q4 brings two more SKYWAY readouts; each is a fresh chance to disappoint in a stock that has already repriced once.
4. Valuation dependence. At ~$92, Spyre trades on the TL1A scarcity premium — the pure-play role is the value, and anything that erodes it erodes the multiple faster than the pipeline.

This is now a one-catalyst story with a date. Size for September, and treat the Q4 baskets as free options behind it.